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ABSTRACT 
BACKGROUND: We investigated the poorly understood impact of declining malaria 
transmission on maintenance of antibodies to P. falciparum merozoite antigens and infected 
erythrocytes (IEs), including functional immunity. 
METHODS: In a 3-year longitudinal cohort of 300 Kenyan children, antibodies to different 
merozoite AMA1 and MSP2 alleles, IE surface antigens, and antibody functional activities were 
quantified. 
RESULTS: Over a period in which malaria transmission declined markedly, AMA1 and MSP2 
antibodies decreased substantially; estimated half-lives of antibody duration were 0.8 and 1-3 
years, respectively. However, 69-74% of children maintained their sero-positivity to AMA1 
alleles and 42-52% to MSP2 alleles. Levels and prevalence of anti-merozoite antibodies were 
consistently associated with increasing age and concurrent parasitaemia. Antibodies promoting 
opsonic phagocytosis of merozoites declined rapidly (half-life 0.15 years). In contrast, 
complement-fixing antibodies to merozoites did not decline and antibodies to IE surface antigens 
expressing virulent phenotypes were much better maintained (half-life 4-10 years). 
CONCLUSIONS: A decline in malaria transmission is associated with reduction in naturally-
acquired immunity. However, loss of immunity is not universal; some key functional responses 
and antibodies to IEs were better maintained and these may continue to provide some protection. 
Findings have implications for malaria surveillance and control measures and informing vaccine 
development. 
 
Key words: malaria, P. falciparum, immunity, children, Africa, antibodies, complement, 
phagocytosis
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INTRODUCTION  
In areas of moderate to high malaria endemicity, naturally-acquired immunity to malaria 
is characterized by protection against clinical disease and control of high density parasitaemia [1, 
2]. Antibodies play a major role in naturally-acquired immunity to Plasmodium falciparum 
malaria [1, 2] and predominantly target the blood-stages, including merozoites and infected 
erythrocytes (IEs). Anti-malarial antibodies typically increase with age, exposure and 
transmission intensity and the link between antibody acquisition and the level of malaria 
exposure has been largely established (reviewed in [3], [4]). As a result of intensified control 
efforts, and other factors (e.g. change in malaria policies and practices, changes in users’ and 
health providers’ behaviours), P.falciparum transmission has declined in many regions in recent 
years, and these declines have been associated with higher rates and severity of clinical malaria 
[5-7], which may be attributed to declining naturally-acquired immunity in populations. While 
there is evidence that declines in malaria transmission are associated with reductions in 
antibodies to blood-stage antigens [8-10], what is less clear is how rapidly antibody levels to 
different targets decline in the context of declining transmission, whether significant humoral 
immune responses are maintained after reductions in transmission, or the impact of changing 
transmission on functional antibody responses.  
Reported estimated half-lives of antibodies to blood-stage malaria antigens range from 
weeks to years (reviewed in [3]). These data are mainly for merozoite antigens, whereas there are 
limited data on the maintenance of functional antibody responses associated with protection (e.g. 
opsonisation of merozoites for phagocytic clearance and complement fixation on merozoites) 
[11, 12]. The maintenance and function of antibodies to IE surface antigens or merozoite 
antigens might be impacted by their different presentation to the immune system, but there are 
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limited data comparing the decay of antibodies to different blood-stage antigens. Also, different 
kinetics of antibody responses specific for different alleles might give some indication of the 
relative prevalence and dynamics of circulating parasite strains, and antibody decay rates for 
different alleles may vary [13, 14]. Greater knowledge on how declining malaria transmission 
affects maintenance of immunity, especially functional immune responses, is required in order to 
identify biomarkers of exposure, evaluate the impact of interventions, and help identify 
populations at risk (reviewed in [4]), as well as inform the development of long-lasting vaccines.  
Here, we examined the impact of declining P. falciparum transmission on the 
maintenance of antibodies to P. falciparum antigens in a 3-year longitudinal cohort of Kenyan 
children. We measured antibody responses to two representative merozoite antigens, apical 
membrane antigen 1 (AMA1) and merozoite surface protein 2 (MSP2). The two antigens are 
important targets of naturally-acquired antibodies, including functional antibodies, that have 
been associated with protection against clinical disease in our study population [11, 15, 16], and 
are established vaccine candidates [17, 18]. We included different alleles of AMA1 and MSP2 to 
assess patterns of allele-specific antibodies over time. We examined the acquisition of antibody 
responses in relation to age and parasitaemia over time, and calculated antibody decay rates. 
Furthermore, we det rmined the maintenance of functional antibodies to merozoites and 
compared maintenance of antibodies between merozoite and IE surface antigens to determine 
whether different response-types are maintained differently.  
 
METHODS 
Study design and population 
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This cohort study was conducted in Ngerenya (Kilifi district, Kenya) [19] where biannual 
malaria transmission occurs (May-July and November-December), and comprised ~300 children 
aged 0.5-10 years who were followed for 3 years from May 2002 to October 2004. This was an 
aging cohort; median age 3.7 years in May 2003 and 5.3 years in October 2004. Venous blood 
was collected in May (high transmission) and October (low transmission) in 2002-2004 (6 time-
points). The same children were seen at most time points and 186 children were present at all 6 
sampling points. At each time-point, presence of P. falciparum parasitaemia was assessed among 
all children by light microscopy. Active malaria case detection was performed weekly; children 
who were febrile (temperature ≥ 37.5°C) or had a recent history of fever or illness had a blood 
smear performed. Malaria was defined as any parasitaemia with fever in children <1 year and a 
parasitaemia ≥2,500/µl of blood with fever in children ≥1 year [20]. Ethics approval was 
obtained from the Ethics Committee of the Kenya Medical Research Institute, and the Alfred 
Health Human Research and Ethics Committee. Parents/guardians of each participant provided 
written informed consent. 
For cross-sectional analyses of antibody prevalence at each time-point, all available 
children were included (n=270 to 298). For longitudinal analysis of changes in antibody levels 
over time, only children who were sampled at all time points were included (n=186). For 
estimating antibody half-life during a period of minimal malaria transmission, only children who 
were sampled at all three time-points that corresponded to the decline in malaria prevalence 
(October 2003, May 2004, October 2004), and were aparasitaemic at the time of sampling and 
during the interval periods, were included. From those, a subset of 71 children (who were 
positive for antibodies to merozoite antigens at October 2003) were selected for analysis of 
maintenance of functional antibodies and antibodies to IEs. 
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Antibody measurements 
IgG among serum samples was measured by standard ELISA, as described [21] using 
recombinant AMA1 (W2mef, HB3, and 3D7 alleles) and MSP2 (3D7 and FC27 alleles), which 
were expressed in E. coli [15, 22]. For functional antibodies to merozoites we used intact 
purified merozoites of the D10 isolate [23]. Merozoite opsonic phagocytosis was performed as 
described elsewhere [24]. Antibody-mediated fixation of C1q to the surface of merozoites, a 
biomarker of classical complement activation that leads to inhibition of merozoite invasion and 
merozoite lysis, was measured as described [25]. IgG reactivity to surface antigens of IEs (3D7 
and IT4var19 isolates) was evaluated using an established flow-cytometry-based approach [26]. 
Further details are provided in Supplementary Methods. 
 
Data Analysis 
Analyses were performed using STATA software. Antibody sero-positivity threshold was 
defined as the mean reactivity of negative controls plus 3 standard deviations [27]. Prevalence of 
antibodies to AMA1 and MSP2 between different age groups and different time-points were 
compared using the Chi-square test. Antibody levels across groups at a single time point were 
compared using Kruskal-Wallis and Mann-Whitney tests. MANOVA for repeated measures 
using the Wilks Lambda criteria was used to test for differences in antibody levels over time on 
the T – 1 absolute differences between subsequent measurements. Estimated mean antibodies 
half-lives were determined from linear mixed effect models as previously described [21].  
 
RESULTS 
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Declining malaria transmission associated with decreased levels of antibodies to merozoite 
antigens 
Antibodies to merozoite antigens AMA1 and MSP2, including different alleles, were 
measured at each of the six cross-sectional surveys from May 2002 to October 2004. In the later 
part of the study, October 2003 to October 2004, malaria transmission significantly decreased. 
Parasite prevalence at cross-sectional bleeds dropped from 14.0% (May-2002) to 3.7% (October-
2004) (Figure 1A). The incidence of any detectable parasitaemia (of any density) was <3% by 
active surveillance between May and October 2004 (Table S2).  
This decline in transmission was accompanied by significant reductions in the prevalence 
of antibodies to all AMA1 (Table 1) and MSP2 alleles (Table 2) within most age groups over 
that period (2-8-year olds for AMA1 and MSP2-FC27; 3 and 5-7-year olds for MSP2-3D7). 
Furthermore, from October 2003 levels of antibodies to all AMA1 and MSP2 alleles 
significantly decreased between cross-sectional bleeds (Figure 1B; Tables 3, 4) (P < 0.001).  
Despite declining transmission and immune responses, AMA1 and MSP2 antibody 
prevalence and levels were consistently higher among older children at every time point (Table 1 
and 2; P < 0.001 to P = 0.033; P < 0.001, respectively), such that median antibody levels were 
significantly higher amongst 7-10-year olds compared with 1-3-year olds (P < 0.001; Tables 2, 
3, S3, S4 and S5). Similar associations with age were observed for antibody responses to all 
alleles of AMA1 and MSP2 and to schizont protein extract used as a proxy for P. falciparum 
blood-stage exposure (Table S6). The prevalence of antibodies to MSP2-3D7 was higher than to 
MSP2-FC27 allele, reflecting the moderately higher prevalence of MSP2-3D7 genotype 
infections in the study population [28]. 
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At each time point, children with parasitaemia (including any density) at time of 
sampling had higher levels of antibodies to all alleles of AMA1 (Tables 3, 4, S3) and MSP2 
(Tables 4, S5) compared to aparasitaemic children (P < 0.01). This suggests that on-going 
exposure to infection helped maintain higher levels in the cohort, and the declining transmission 
and exposure therefore resulted in declining antibody levels. Associations between antibodies 
and increasing age were observed in aparasitaemic children, but less consistently amongst 
parasitaemic children. Similar results were observed for antibody responses to all alleles of 
MSP2 and AMA1 and to schizont extract (Table S6). 
 
Decay rates of antibodies to merozoite antigens with declining malaria transmission  
We examined the rate of decline of levels and prevalence of antibodies to AMA1 and 
MSP2 between October 2003 and October 2004 as malaria transmission declined. While there 
was inter-individual variation and fluctuation over time, overall cohort antibody levels to all 
AMA1 and MSP2 alleles significantly eclined in all age groups during this interval (Figure 1B; 
Tables 1, 2). We estimated the mean half-life of antibodies to AMA1 or MSP2 between October 
2003 and October 2004 [21] in children who were seropositive at the October 2003 contact point 
and had no recorded parasitaemia at the time of sample collection or during this 12-month period 
of follow-up (Figure 1B). Estimated half-lives of antibodies to the different AMA1 alleles were 
similar at around 0.8 years (9.6 months; range 0.78-0.83) and comparable to antibodies to MSP2 
FC27 allele (1.1 years), but substantially shorter than that of antibodies to MSP2 3D7 allele (3.4 
years). No significant differences in decay rates were found between age groups, although 
confidence intervals were wide. 
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Despite declining malaria transmission, many children among the whole cohort 
maintained their seropositive status for antibodies to AMA1 and/or MSP2 (Table 5); 69-73% of 
children who were seropositive at October 2003 maintained sero-positivity to each AMA1 allele 
at October 2004, but overall antibody reactivity had declined substantially. For MSP2 alleles, 42-
52% who were positive at October 2003 remained seropositive at October 2004. Not all children 
had declining antibodies during this period. For example, for AMA1-W2mef 28.5% of children 
showed no significant decline between October 2003 to May 2004 (33.8% and 31% for 3D7 and 
HB3 alleles); for MSP2, proportions were 32.1% and 27.8% for 3D7 and FC27 alleles, 
respectively. 
 
Maintenance of functional antibodies to merozoites and antibodies to infected erythrocytes 
surface antigens 
We evaluated maintenance of functional antibodies to merozoites as malaria transmission 
declined. We studied antibodies that promote opsonic phagocytosis of merozoites and antibodies 
that fix complement on the surface of merozoites as these two functional measures of merozoite 
antibodies have been associated with protective immunity in longitudinal studies of children [24, 
25, 29]. We measured antibody levels over the last 12 months of the study (October 2003 to 
October 2004) among children who had no recorded episode of parasitaemia during that period.  
Antibodies with opsonic phagocytosis activity declined rapidly with a half-life of just 0.15 
years (1.8 months; 95% reference range 0.09-0.4 years), significantly shorter than the half-lives 
of antibodies to individual merozoite antigens (Figure 2A). Despite declining levels, the 
prevalence of phagocytosis-promoting antibodies remained consistently high, from 92.3% in 
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October 2003 to 89.4% in October 2004 suggesting some level of functional opsonic 
phagocytosis activity is retained for long periods of time.  
 In contrast, levels of complement-fixing antibodies did not appreciably decline (0.7-∞) 
(Figure 2B). Accordingly, the proportion of children seropositive for complement-fixing 
antibodies remained constant from 78% in October 2003 to 81.3% in October 2004. However, 
there was a wide range of observed responses with some individuals exhibiting a measurable 
decline and others remaining stable throughout. No significant correlations were found between 
the measures of functional antibodies to merozoites, consistent with the different rates of decline. 
 We measured levels of antibodies to surface antigens of IEs given they could be 
maintained differently to merozoite antigens due to their different presentation to the immune 
system (Figures 2C, 2D). We previously reported that these antibodies are acquired in an age-
dependent manner [12, 24] in our study population and predominantly target PfEMP1 [30, 31]. 
We included two genetically distinct isolates expressing PfEMP1 types associated with virulent 
phenotypes and disease pathogenesis: i) isolate IT4var19 expresses var19 (containing a DC8 
arrangement) which mediates adhesion to cerebral endothelial cells; ii) a 3D7 isolate we 
identified that expresses group A var genes (including a DC13 arrangement) associated with 
virulent properties (Table S1). Antibodies to IE surface antigens expressed by both isolates were 
relatively stable as malaria transmission declined (half-lives 10.5 [3.2-∞] and 4 [1.4-∞] years for 
3D7 and IT4var19 IEs, respectively).  
Collectively these results show that while total levels of antibodies to individual 
merozoite antigens are sensitive to changes in malaria transmission, specific antibody functional 
activity is better maintained, especially their capacity to fix complement. Antibodies to IEs 
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expressing PfEMP1 variants associated with disease pathogenesis also appear to be better 
maintained.  
 
DISCUSSION 
There is concern that recent reductions in malaria transmission in many endemic 
countries [6, 32-35] may lead to rapid declines in naturally-acquired immunity, leaving many at 
increased risk of malaria and severe complications. Declining P. falciparum prevalence in our 
cohort was accompanied by decreasing antibodies to two key merozoite antigens, AMA1 and 
MSP2; this was consistent across different alleles of MSP2 and AMA1. In the context of low 
parasite prevalence and absence of clinical malaria, most children maintained seropositivity to 
AMA1, whereas fewer children retained seropositivity for MSP2. The broad similarity in 
estimated half-lives of antibodies to AMA1 and MSP2 (approximately 9 months and 1-3 years, 
respectively, with overlapping confidence intervals) suggests that differences in maintenance of 
sero-positivity could be related to lower starting levels of antibodies to MSP2. 
Different kinetics of antibody responses specific for different alleles might give some 
indication of the relative prevalence and dynamics of circulating parasite strains [13, 14]. 
Antibody responses to AMA1-W2mef increased from May 2002 before declining and reaching 
levels comparable to the other two AMA1 alleles by October 2003. This coincided with an 
increase in the incidence of parasitaemia (of any density) and clinical malaria between May 2002 
and May 2003; P. falciparum strains carrying a W2mef-like AMA1 allele may have been more 
prevalent during that time. The higher prevalence of antibodies to MSP2-3D7 is consistent with 
infections with this genotype being moderately more prevalent. 
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Rather than determining absolute decay rates of antibodies in the absence of any 
exposure, we estimated antibody maintenance in a practical setting where malaria transmission 
had dramatically reduced, an increasingly common situation globally. Maintenance of antibodies 
was highly variable among individuals, from rapid decay to no decline. Overall estimated half-
lives of 1-3 years for antibodies to AMA1 or MSP2 indicate that antibodies to merozoite 
antigens decline relatively quickly; however, such decay rates and the wide variation in antibody 
maintenance among individuals imply that detectable levels of these antibodies could be 
maintained for several years. Our findings are largely consistent with studies in pregnant women 
[21] and a small study of adults in South-East Asia [36]. In contrast, some studies in African 
children reported rapid declines in antibodies to merozoite antigens when measured immediately 
after treatment for acute malaria [37, 38]. Given antibodies initially decay rapidly following an 
acute infection, estimates of antibody half-lives will be much shorter if measured following an 
acute episode than measured in uninfected subjects as we have done [3, 39, 40]. Published 
evidence suggests impairment in the induction of B cell memory to malaria [41], which may 
partly explain the lack of sustained responses.  
We complemented observations on the dynamics of antibody levels by providing 
important new data on maintenance of functional antibodies to merozoite antigens on which very 
little is currently known. We measured antibodies that mediate opsonic phagocytosis and 
complement fixation on merozoites as these have emerged as likely mechanisms of immunity 
and promising functional correlates of immunity [12, 24, 25, 29]. Functional complement-fixing 
antibodies to merozoites were better maintained than total antibodies to merozoite antigens. This 
may suggest that complement fixation requires only low levels of antibodies and antibody levels 
must decline below a certain threshold before functional activity is lost. Alternatively, 
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complement fixation might be mediated by specific antibodies that are better maintained over 
time due to their role in immunity. Functional activity is dependent on multiple antibody 
properties, such as affinity, subclass, allotype, glycosylation, and epitope specificity, and not just 
total antibody levels [42]. In contrast, opsonic phagocytosis-promoting antibodies rapidly 
declined, suggesting this functional response is more sensitive to decrease in antibody levels. 
However, most children remained positive for opsonic phagocytosis activity over the 12-month 
period even though overall activity did decline quickly. While antibody decay was estimated 
among children who had no parasitaemia detected during surveillance using microscopic 
evaluation of blood smears, it is possible that we missed some parasitaemic events; data on 
parasitaemia detected using more sensitive PCR methods was not available. Our findings 
indicate that some forms of immunity may be better maintained, and highlight the need for 
assessing antibody function in population studies rather than simply antibody levels. The 
sustained persistence of some key elements of immunity is consistent with epidemiologic 
evidence suggesting that some level of immunity may be maintained for extended periods after 
decline or interruption malaria transmission [3]. 
 Our previous studies showed that the prevalence of growth-inhibitory antibodies in this 
cohort was low [43]; therefore these were not evaluated. However, we previously showed that 
growth-inhibitory antibodies were higher at times of higher malaria transmission [43]. It was not 
possible to investigate the relationship between declining immunity and subsequent risk of 
malaria in this study. Prior studies [15, 44] have suggested that there is a threshold magnitude of 
antibodies required to mediate immunity. Our results finding a decline in total antibodies to 
merozoites suggest that susceptibility to malaria is likely to have increased in children as a result 
of this decline. 
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Antibody acquisition longevity may also vary according to antigen specificity and 
parasite life-stage [21, 38, 45]; therefore we compared maintenance of antibodies to merozoite 
antigens versus IE surface antigens. For our studies we used isolates that expressed PfEMP1 
variants associated with disease pathogenesis as we reasoned that antibodies to these variants are 
likely to have a role in immunity. Levels of antibodies to IE surface antigens were better 
maintained than levels of antibodies to merozoite surface antigens despite a lower sero-positivity 
at the beginning of the study. This may be due to their different presentation to the immune 
system and suggests that some individuals can maintain effective antibody-mediated immunity to 
IE surface antigens. We have previously reported that the majority (>80%) of antibody reactivity 
to IEs targets PfEMP1 [30, 31]; however, a minor proportion of antibody reactivity may target 
other surface antigens. IE surface antibodies correlate with functional opsonic phagocytosis 
activity [31], a mechanism thought to be important in mediating IE clearance.  Our results 
suggest inherent differences in maintenance of antibodies to antigens of IEs versus merozoites; 
they also suggest that generating long-lived immune responses to malaria is possible. Similarly, 
we previously found antibodies to PfEMP1 had much slower decay rates than antibodies to 
merozoite antigens in pregnant women [21]. Relatively short-lived antibodies suggest an inherent 
weakness in naturally-acquired immunity to merozoites. Understanding differences in antibody 
maintenance between antibodies to merozoites and IEs may yield important insights to guide 
vaccine design. Antibodies may be valuable biomarkers to enhance malaria surveillance [4]. 
Understanding acquisition and maintenance of antibodies is crucial in assessing their utility in 
serosurveillance approaches. Our results suggest antibodies to AMA1 and MSP2 are relatively 
sensitive biomarkers of changes in malaria transmission, consistent with findings in other 
populations [46, 47].  
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In conclusion, by evaluating antibodies to merozoite antigens, IE surface antigens, and 
functional antibodies in a longitudinal cohort of children, we have provided significant new 
insights into the impact of declining malaria on immunity. The data provide estimates of decay 
rate of antibodies in a practical context of declining population malaria transmission. 
Furthermore, the findings indicate that certain elements of immunity may persist for extended 
periods following reduction in transmission. There was a decline in the prevalence and levels of 
antibodies to merozoite antigens AMA1 and MSP2 associated with falling prevalence of P. 
falciparum amongst children. Opsonic phagocytosis-promoting antibodies decayed more rapidly 
following declining transmission, whereas complement-fixing antibodies to merozoites or 
antibodies to IE surface antigens were much better maintained. Understanding the great 
variability among individuals in antibody maintenance may be very valuable for informing 
vaccine and biomarker development and implementation. With upscaling of malaria control and 
progress towards elimination in some regions, results from this study provide important insights 
on how immunity may be affected by changes in malaria transmission intensity and provide 
information to aid selection of biomarkers for monitoring transmission and identifying 
susceptible populations or groups for targeted interventions. 
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FIGURE LEGENDS 
 
Figure 1. Decline in parasite prevalence over the study period.  
A. Decline of prevalence of parasite prevalence at each cross sectional bleed. At each time-point, 
presence of P. falciparum parasitaemia was assessed by light microscopy. Data are presented as 
parasite prevalence (of any density), with the number of parasitaemic children over the total 
number of children tested indicated for each cross sectional survey time point. 
B. Number of episodes of malaria at each cross sectional bleed. Data are presented as number of 
episodes of malaria (i.e. any parasitaemia accompanied by fever in children <1 year and a 
parasitaemia ≥2,500 IEs/µl of blood accompanied by fever in children ≥1 year) for each time 
point. The percentage of children with malaria is indicated for each cross sectional survey time 
point.  
C. Mean antibody levels to merozoite antigens over the study period. Antibody levels against 
different alleles of AMA1 and MSP2 were measured by standard ELISA. Data are presented as 
locally weighted scatter plot smoothing (LOWESS) curves (the numbers of subjects included at 
each time point are: May 2002, 298; Oct 2002, 294; May 2003, 285; Oct 2003, 294; May 2004, 
279; Oct 2004, 273). The mean half-life of antibodies is shown for each antibody; this was 
calculated for the period between October 2013 and October 2014 when malaria transmission 
declined, and included children who were present at each time-point and had no malaria 
parasitaemia detected during that time period. 
 
Figure 2. Decline in levels of functional antibodies to merozoites and antibodies to IE 
surface antigens over the study period. 
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In a subset of 70 samples, antibody function was measured at three time-points (October 2003, 
May 2004, and October 2004). The predicted mean antibody levels (and 95% confidence 
intervals shown in grey) over time are shown. Day 0 represents October 2003 with days of 
follow-up indicated on the X-axis. Mean functional antibody half-lives were calculated from the 
fixed effects slope component of a mixed effects model and are represented in years. Antibody 
half-life for each antibody measure is as follows: (A) Opsonic phagocytosis of merozoites, 0.15 
(0.09-0.40); (B) complement (C1q) fixation on merozoites (0.70-∞); (C) antibodies to surface 
antigens of 3D7 IEs, 10.5 (3.2-∞), and (D) antibodies to surface antigens A4var19 IEs 4.0 (1.4-
∞). 
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Table 1. Seropositivity to AMA1 alleles by age at each cross-sectional survey 
Age (years) 
Seroprevalence (95% CI) 
  
May 2002
a 
October 2002
a
 May 2003
a
 October 2003
a
 May 2004
a
 October 2004
a
 
 
P-value
b 
AMA1 (W2mef)  
0 26.7 (10.6 - 42.9) 67.6 (52.3 - 83) 26 (9.1 - 42.9) 43.5 (22.7 - 64.3) 19.1 (1.8 - 36.4) 33.4 (8.6 - 58.2) 
 
0.182 
1 14.6 (4.5 - 24.8) 21.9 (7.3 - 36.5) 34.7 (15.9 - 53.4) 11.8 (0.8 - 22.9) 16 (1.3 - 30.8) 8.4 (-3.1 - 19.7) 
 
0.385 
2 33.4 (18.3 - 48.4) 48.8 (32.8 - 64.7) 11.4 (1.9 - 20.9) 15.7 (2.8 - 28.5) 6.5 (-2.4 - 15.3) 3.2 (-3.1 - 9.3) 
 
<0.001 
3 48.8 (33.3 - 64.4) 59 (43.3 - 74.7) 34.4 (17.6 - 51.2) 43.3 (27 - 59.5) 32.5 (17.1 - 47.8) 17.9 (3.4 - 32.4) 
 
0.002 
4 50 (32.4 - 67.7) 76.7 (61.3 - 92.2) 40 (24.6 - 55.5) 47.7 (32.3 - 63) 17.3 (3.2 - 31.3) 33.4 (16.1 - 50.6) 
 
0.001 
5 61.8 (47.6 - 75.9) 71.5 (58.6 - 84.3) 48.3 (29.7 - 66.9) 46.2 (26.6 - 65.8) 45.5 (28.2 - 62.8) 42.5 (25.3 - 59.7) 
 
0.007 
6 65.8 (50.5 - 81.2) 75.9 (60 - 91.8) 52.8 (36.2 - 69.4) 62 (47 - 76.9) 54.2 (33.8 - 74.7) 41.7 (21.5 - 62) 
 
0.032 
7 74 (55.5 - 92.4) 82.9 (70.2 - 95.6) 71 (54.7 - 87.3) 52 (32 - 72.1) 57.9 (42 - 73.9) 55.3 (39.2 - 71.4) 
 
0.007 
8c - 100 (0 - 0) 75 (55.5 - 94.6) 81.9 (68.4 - 95.3) 72 (54 - 90.1) 41.7 (21.5 - 62) 
 
0.005 
9c - - - - 81.3 (61.5 - 101.1) 72 (54 - 90.1) 
 
0.506 
P-valued <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
  
AMA1(HB3)  
0 26.7 (10.6 - 42.9) 56.8 (40.6 - 73.1) 37.1 (18.4 - 55.7) 34.8 (14.8 - 54.8) 23.9 (5.1 - 42.6) 33.4 (8.6 - 58.2) 
 
0.361 
1 14.6 (4.5 - 24.8) 9.4 (-1 - 19.7) 34.7 (15.9 - 53.4) 14.8 (2.6 - 26.9) 12 (-1.1 - 25.1) 8.4 (-3.1 - 19.7) 
 
0.619 
2 33.4 (18.3 - 48.4) 20.6 (7.7 - 33.5) 25 (12.1 - 38) 21.9 (7.3 - 36.5) 9.7 (-1 - 20.4) 3.2 (-3.1 - 9.3)  0.001 
3 46.4 (30.9 - 61.9) 46.2 (30.3 - 62.1) 31.3 (14.9 - 47.7) 43.3 (27 - 59.5) 32.5 (17.1 - 47.8) 17.9 (3.4 - 32.4)  0.017 
4 53.2 (35.5 - 70.8) 66.7 (49.5 - 83.9) 55 (39.4 - 70.7) 45.3 (30 - 60.6) 27.6 (11 - 44.3) 30 (13.3 - 46.8)  0.002 
5 68.1 (54.6 - 81.7) 57.2 (43.1 - 71.3) 62.1 (44.1 - 80.2) 46.2 (26.6 - 65.8) 45.5 (28.2 - 62.8) 39.4 (22.4 - 56.4)  0.004 
6 79 (65.8 - 92.2) 55.2 (36.7 - 73.7) 61.2 (44.9 - 77.4) 57.2 (42 - 72.4) 54.2 (33.8 - 74.7) 37.5 (17.7 - 57.4)  0.004 
7 74 (55.5 - 92.4) 77.2 (63 - 91.4) 83.9 (70.7 - 97.1) 52 (32 - 72.1) 52.7 (36.5 - 68.8) 52.7 (36.5 - 68.8)  0.002 
8c - 100 (0 - 0) 85 (68.9 - 101.2) 84.9 (72.4 - 97.4) 80 (64 - 96.1) 45.9 (25.4 - 66.3)  0.002 
9c - - - - 75 (53 - 97.1) 76 (58.9 - 93.2)  0.943 
P-valued <0.001 <0.001 <0.001 <0.001 <0.001 <0.001   
AMA1(3D7)  
0 23.4 (7.9 - 38.8) 48.7 (32.3 - 65.1) 29.7 (12.1 - 47.3) 26.1 (7.7 - 44.6) 23.9 (5.1 - 42.6) 26.7 (3.4 - 50)  0.384 
1 8.4 (0.4 - 16.3) 3.2 (-3.1 - 9.3) 34.7 (15.9 - 53.4) 20.6 (6.8 - 34.5) 8 (-3 - 19) 12.5 (-1.1 - 26.1)  0.386 
2 35.9 (20.6 - 51.3) 20.6 (7.7 - 33.5) 13.7 (3.4 - 24) 18.8 (5 - 32.6) 13 (0.9 - 25) 6.3 (-2.4 - 14.9)  0.002 
3 46.4 (30.9 - 61.9) 35.9 (20.6 - 51.3) 28.2 (12.3 - 44.1) 37.9 (22 - 53.8) 29.8 (14.8 - 44.8) 17.9 (3.4 - 32.4)  0.027 
4 40.7 (23.3 - 58) 63.4 (45.8 - 81) 47.5 (31.8 - 63.3) 40.5 (25.4 - 55.6) 17.3 (3.2 - 31.3) 33.4 (16.1 - 50.6)  0.017 
5 63.9 (49.9 - 77.8) 49 (34.8 - 63.2) 51.8 (33.2 - 70.4) 46.2 (26.6 - 65.8) 39.4 (22.4 - 56.4) 30.4 (14.4 - 46.3)  0.003 
6 71.1 (56.4 - 85.8) 55.2 (36.7 - 73.7) 50 (33.4 - 66.7) 57.2 (42 - 72.4) 41.7 (21.5 - 62) 33.4 (14 - 52.7)  0.004 
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7 65.3 (45.3 - 85.3) 68.6 (53 - 84.3) 77.5 (62.4 - 92.5) 52 (32 - 72.1) 50 (33.9 - 66.2) 50 (33.9 - 66.2)  0.022 
8c - 100 (0 - 0) 75 (55.5 - 94.6) 87.9 (76.6 - 99.3) 76 (58.9 - 93.2) 41.7 (21.5 - 62)  0.003 
9c - - - - 81.3 (61.5 - 101.1) 72 (54 - 90.1)  0.506 
P-valued <0.001 <0.001 <0.001 <0.001 <0.001 <0.001   
 
Notes 
a Cross sectional survey when blood was collected. 
b P-values calculated using a Chi-square test for trend for IgG prevalence in the same age group at different cross sectional bleeds (P-values ≤ 0.05 indicated in bold type). 
c Missing values are due to a lack of children in that age group.  
d P-values calculated using a Chi-square test for trend for IgG prevalence in different age groups at the same cross sectional bleed (P-values ≤ 0.05 indicated in bold type). 
All samples included in analysis. 
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Table 2. Seropositivity to MSP2 alleles by age at each cross-sectional survey  
Age (years) 
Seroprevalence (95% CI) 
  
May 2002
a 
October 2002
a
 May 2003
a
 October 2003
a
 May 2004
a
 October 2004
a
 
 
P-value
b 
MSP2(3D7) 
0 10 (-1 - 21) 2.8 (-2.7 - 8.1) 3.8 (-3.6 - 11) 0 (0 - 0) 0 (0 - 0) 6.7 (-6.5 - 19.8) 
 
0.246 
1 10.5 (1.7 - 19.2) 3.2 (-3.1 - 9.3) 3.9 (-3.8 - 11.5) 0 (0 - 0) 4 (-3.9 - 11.9) 4.2 (-4.1 - 12.4) 
 
0.150 
2 15.4 (3.9 - 27) 0 (0 - 0) 6.9 (-0.8 - 14.4) 3.2 (-3.1 - 9.3) 6.5 (-2.4 - 15.3) 3.2 (-3.1 - 9.3) 
 
0.156 
3 31.8 (17.3 - 46.2) 10.3 (0.6 - 20) 0 (0 - 0) 16.3 (4.2 - 28.4) 13.6 (2.3 - 24.8) 3.6 (-3.5 - 10.7) 
 
0.013 
4 18.8 (5 - 32.6) 13.4 (1 - 25.8) 20 (7.4 - 32.7) 19.1 (7 - 31.2) 6.9 (-2.6 - 16.4) 10 (-1 - 21) 
 
0.249 
5 49 (34.5 - 63.5) 14.3 (4.4 - 24.3) 13.8 (1 - 26.7) 3.9 (-3.8 - 11.5) 9.1 (-1 - 19.1) 6.1 (-2.3 - 14.4) 
 
<0.001 
6 47.4 (31.3 - 63.6) 27.6 (11 - 44.3) 27.8 (12.9 - 42.7) 31 (16.8 - 45.2) 8.4 (-3.1 - 19.7) 0 (0 - 0) 
 
<0.001 
7 52.2 (31.3 - 73.2) 20 (6.5 - 33.6) 22.6 (7.6 - 37.7) 28 (10 - 46.1) 23.7 (10 - 37.5) 10.6 (0.6 - 20.5) 
 
0.009 
8c - 0 (0 - 0) 30 (9.4 - 50.7) 27.3 (11.8 - 42.8) 28 (10 - 46.1) 25 (7.3 - 42.8) 
 
0.860 
9c - - - - 37.5 (12.9 - 62.2) 28 (10 - 46.1) 
 
0.529 
P-valued <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
  
MSP2(FC27) 
0 13.4 (1 - 25.8) 5.5 (-2.1 - 12.9) 7.5 (-2.8 - 17.6) 4.4 (-4.3 - 13) 4.8 (-4.7 - 14.2) 0 (0 - 0) 
 
0.113 
1 18.8 (7.6 - 30) 6.3 (-2.4 - 14.9) 7.7 (-2.8 - 18.2) 0 (0 - 0) 0 (0 - 0) 8.4 (-3.1 - 19.7) 
 
0.012 
2 12.9 (2.2 - 23.5) 10.3 (0.6 - 20) 6.9 (-0.8 - 14.4) 3.2 (-3.1 - 9.3) 6.5 (-2.4 - 15.3) 0 (0 - 0) 
 
0.026 
3 31.8 (17.3 - 46.2) 15.4 (3.9 - 27) 9.4 (-1 - 19.7) 24.4 (10.3 - 38.4) 16.3 (4.2 - 28.4) 3.6 (-3.5 - 10.7) 
 
0.026 
4 18.8 (5 - 32.6) 40 (22.1 - 58) 20 (7.4 - 32.7) 21.5 (8.9 - 34.1) 6.9 (-2.6 - 16.4) 10 (-1 - 21) 
 
0.024 
5 23.5 (11.2 - 35.7) 18.4 (7.4 - 29.4) 20.7 (5.7 - 35.8) 23.1 (6.5 - 39.7) 9.1 (-1 - 19.1) 6.1 (-2.3 - 14.4) 
 
0.031 
6 31.6 (16.6 - 46.7) 20.7 (5.7 - 35.8) 27.8 (12.9 - 42.7) 26.2 (12.7 - 39.8) 0 (0 - 0) 4.2 (-4.1 - 12.4) 
 
0.003 
7 39.2 (18.7 - 59.7) 34.3 (18.3 - 50.4) 35.5 (18.3 - 52.7) 20 (4 - 36.1) 10.6 (0.6 - 20.5) 10.6 (0.6 - 20.5) 
 
0.000 
8c - 0 (0 - 0) 50 (27.5 - 72.6) 45.5 (28.2 - 62.8) 36 (16.8 - 55.3) 12.5 (-1.1 - 26.1) 
 
0.012 
9c - - - - 50 (24.6 - 75.5) 36 (16.8 - 55.3) 
 
0.381 
P-valued 0.033 0.004 <0.001 <0.001 <0.001 0.001 
  
 
Notes 
a
 Cross sectional survey when blood was collected. 
b P-values calculated using a chi2 test for trend for IgG prevalence in the same age group at different cross sectional bleeds (P-values ≤ 0.05 indicated in bold type). 
c Missing values are due to a lack of children in that age group. 
d P-values calculated using a chi2 test for trend for IgG prevalence in different age groups at the same cross sectional bleed (P-values ≤ 0.05 indicated in bold type). 
All samples included in analysis. 
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Table 3. Levels of antibodies to AMA1 by age group and parasitaemia status 
AMA1 (W2mef 
allele)  
 
All Samples 
 
Aparasitemic 
 
Parasitemic 
 
0 
years 
1-3 
years 
4-6 
years 
7-10 
years 
P-
valu
ea 
 
0 
years 
1-3 
years 
4-6 
years 
7-10 
years 
P-
valu
ea 
 
0 years 
1-3 
years 
4-6 
years 
7-10 
years 
P-
valu
ea 
                    
May 
2002b 
Nc 
 
30 128 117 23 
  
30 109 93 15 
  
0 19 24 8 
 
 
Me
dia
n 
 
0.04 0.01 0.24 0.24 
<0.0
01d  
0.04 -0.01 0.10 0.44 
<0.0
01d  
0.00 0.65 0.89 1.30 
0.71
0 
 
IQR 
 
(-0.01 
- 0.18) 
(-0.02 
- 0.17) 
(0.03 - 
1.18) 
(0.1 - 
1.9)   
(-0.01 
- 0.18) 
(-0.03 
- 0.09) 
(0.02 - 
0.59) 
(0.13 - 
1.67)   
(0 - 0) 
(0.11 - 
1.67) 
(0.43 - 
2.02) 
(0.06 - 
2.19)  
Octobe
r 2002b 
Nc 
 
37 110 108 36 
  
36 105 99 31 
  
1 5 9 5 
 
 
Me
dia
n 
 
0.70 0.17 0.66 0.66 
<0.0
01d  
0.73 0.17 0.63 1.60 
<0.0
01d  
-0.04 1.27 1.29 0.86 
0.43
3 
 
IQR 
 
(0.1 - 
1.43) 
(0.02 - 
0.47) 
(0.2 - 
1.66) 
(0.51 - 
2.37)   
(0.12 - 
1.48) 
(0.01 - 
0.39) 
(0.18 - 
1.63) 
(0.49 - 
2.34)   
(-0.04 - 
-0.04) 
(1.13 - 
2.2) 
(0.27 - 
2.19) 
(0.66 - 
2.47)  
May 
2003b 
Nc 
 
27 102 105 51 
  
26 93 88 40 
  
1 9 17 11 
 
 
Me
dia
n 
 
0.01 0.01 0.07 0.07 
<0.0
01d  
0.01 0.00 0.05 0.30 
<0.0
01d  
-0.04 0.04 0.58 2.21 
0.01
3d 
 
IQR 
 
(-0.03 
- 0.13) 
(-0.03 
- 0.1) 
(0 - 
0.73) 
(0.08 - 
2.06)   
(-0.02 
- 0.13) 
(-0.02 
- 0.07) 
(0 - 
0.46) 
(0.07 - 
1.51)   
(-0.04 - 
-0.04) 
(-0.04 
- 0.3) 
(0.12 - 
1.53) 
(0.19 - 
2.34)  
Octobe
r 2003b 
Nc 
 
23 103 110 58 
  
23 93 91 45 
  
0 10 18 13 
 
 
Me
dia
n 
 
0.08 0.02 0.14 0.14 
<0.0
01d  
0.08 0.01 0.07 0.31 
<0.0
01d  
0.00 1.08 1.73 2.19 
0.12
3 
 
IQR 
 
(0.02 - 
0.24) 
(-0.01 
- 0.1) 
(0.02 - 
0.78) 
(0.07 - 
1.92)   
(0.02 - 
0.24) 
(-0.01 
- 0.05) 
(0.01 - 
0.49) 
(0.07 - 
1.18)   
(0 - 0) 
(0.21 - 
1.71) 
(0.44 - 
2.13) 
(1.61 - 
2.26)  
May 
2004b 
Nc 
 
21 93 86 79 
  
21 88 84 69 
  
0 5 2 10 
 
 
Me
dia
n 
 
0.00 0.00 0.05 0.05 
<0.0
01d  
0.00 0.00 0.05 0.24 
<0.0
01d  
0.00 1.10 0.22 1.72 
0.11
7 
 
IQR 
 
(-0.02 
- 0.08) 
(-0.02 
- 0.05) 
(0.01 - 
0.28) 
(0.06 - 
1.31)   
(-0.02 
- 0.08) 
(-0.02 
- 0.04) 
(0.01 - 
0.28) 
(0.03 - 
1.02)   
(0 - 0) 
(0.58 - 
1.55) 
(0.1 - 
0.34) 
(0.98 - 
2.03)  
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Octobe
r 2004b 
N
c
 
 
15 84 87 87 
  
15 80 87 81 
  
0 4 0 6 
 
 
Me
dia
n 
 
0.02 -0.01 0.03 0.03 
<0.0
01d  
0.02 -0.02 0.03 0.15 
<0.0
01d  
0.00 0.36 0.00 1.12 
0.28
6 
 
IQR 
 
(-0.01 
- 0.21) 
(-0.03 
- 0.02) 
(-0.02 
- 0.26) 
(0.02 - 
0.88)   
(-0.01 
- 0.21) 
(-0.03 
- 0.01) 
(-0.02 
- 0.26) 
(0.01 - 
0.75)   
(0 - 0) 
(0.26 - 
0.48) 
(0 - 0) 
(0.2 - 
1.5)  
Notes 
a
 P-values calculated using a Kruskal Wallis test (P-values ≤ 0.05 indicated in bold type). 
b Cross sectional survey. 
c
 Number of samples tested by ELISA. Data for the 3D7 and HB3 alleles of AMA1 are provided in the Supplementary Material 
d P-values ≤ 0.05 when comparing antibody levels between children 1-3 years and children 7-10 years using a Mann Whitney U test (P-values not shown). 
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Table 4. Levels of antibodies to MSP2 by age group and parasitaemia status 
MSP2 (3D7 allele) 
All Samples 
 
Aparasitemic 
 
Parasitemic 
0 
years 
1-3 
years 
4-6 
years 
7-10 
years 
P-
valu
ea 
 
0 
years 
1-3 
years 
4-6 
years 
7-10 
years 
P-
valu
ea 
 
0 
years 
1-3 
years 
4-6 
years 
7-10 
years 
P-
valu
ea 
                    
May 
2002b 
Nc 
 
30 128 117 23 
  
30 109 93 15 
  
0 19 24 8 
 
 
Me
dia
n 
 
0.04 0.13 0.33 0.33 
<0.0
01d  
0.04 0.10 0.28 0.29 
<0.0
01d  
0.00 0.89 1.14 1.76 
0.64
0 
 
IQR 
 
(0.02 - 
0.13) 
(0.03 - 
0.4) 
(0.12 - 
1.09) 
(0.11 - 
1.29)   
(0.02 - 
0.13) 
(0.03 - 
0.3) 
(0.12 - 
0.82) 
(0.11 - 
0.87)   
(0 - 0) 
(0.58 - 
1.58) 
(0.16 - 
2.08) 
(0.33 - 
2.43)  
Octobe
r 2002b 
Nc 
 
37 110 108 36 
  
36 105 99 31 
  
1 5 9 5 
 
 
Me
dia
n 
 
0.04 0.05 0.14 0.14 
<0.0
01d  
0.04 0.04 0.13 0.12 
<0.0
01d  
0.01 0.62 0.21 1.65 
0.19
3 
 
IQR 
 
(0.01 - 
0.1) 
(0.02 - 
0.09) 
(0.06 - 
0.34) 
(0.07 - 
0.47)   
(0.02 - 
0.1) 
(0.02 - 
0.08) 
(0.06 - 
0.33) 
(0.07 - 
0.34)   
(0.01 - 
0.01) 
(0.04 - 
0.77) 
(0.14 - 
0.54) 
(0.5 - 
2.43)  
May 
2003b 
Nc 
 
27 102 105 51 
  
26 93 88 40 
  
1 9 17 11 
 
 
Me
dia
n 
 
0.09 0.04 0.13 0.13 
<0.0
01d  
0.10 0.04 0.10 0.14 
<0.0
01d  
0.06 0.12 0.73 1.16 
0.04
8d 
 
IQR 
 
(0.01 - 
0.23) 
(0.01 - 
0.1) 
(0.05 - 
0.43) 
(0.07 - 
0.72)   
(0.01 - 
0.23) 
(0.01 - 
0.09) 
(0.04 - 
0.31) 
(0.06 - 
0.31)   
(0.06 - 
0.06) 
(0.04 - 
0.26) 
(0.2 - 
1.39) 
(0.2 - 
2.56)  
Octobe
r 2003b 
Nc 
 
23 103 110 58 
  
23 93 91 45 
  
10 18 13 0 
 
 
Me
dia
n 
 
0.08 0.06 0.13 0.13 
<0.0
01d  
0.08 0.06 0.10 0.18 
<0.0
01d  
0.43 0.49 1.77 0.00 
0.42
6 
 
IQR 
 
(0.04 - 
0.19) 
(0.02 - 
0.25) 
(0.05 - 
0.41) 
(0.08 - 
0.56)   
(0.04 - 
0.19) 
(0.01 - 
0.16) 
(0.04 - 
0.28) 
(0.07 - 
0.44)   
(0.29 - 
1.03) 
(0.32 - 
0.75) 
(0.32 - 
2.17) 
(0 - 0) 
 
May 
2004b 
Nc 
 
21 93 86 79 
  
21 88 84 69 
  
0 5 2 10 
 
 
Me
dia
n 
 
0.01 0.04 0.08 0.08 
<0.0
01d  
0.01 0.03 0.08 0.17 
<0.0
01d  
0.00 0.22 0.49 0.43 
0.80
9 
 
IQR 
 
(0 - 
0.02) 
(0 - 
0.1) 
(0.04 - 
0.24) 
(0.06 - 
0.6)   
(0 - 
0.02) 
(0 - 
0.09) 
(0.04 - 
0.23) 
(0.04 - 
0.47)   
(0 - 0) 
(0.2 - 
1.53) 
(0.25 - 
0.72) 
(0.17 - 
2.14)  
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Octobe
r 2004b 
N
c
 
 
15 84 87 87 
  
15 80 87 81 
  
0 4 0 6 
 
 
Me
dia
n 
 
0.02 0.04 0.07 0.07 
<0.0
01d  
0.02 0.03 0.07 0.13 
<0.0
01d  
0.00 0.45 0.00 1.63 
0.08
8 
 
IQR 
 
(0.01 - 
0.06) 
(0.01 - 
0.08) 
(0.03 - 
0.14) 
(0.05 - 
0.45)   
(0.01 - 
0.06) 
(0.01 - 
0.07) 
(0.03 - 
0.14) 
(0.05 - 
0.37)   
(0 - 0) 
(0.13 - 
1.33) 
(0 - 0) 
(1.17 - 
2.31)  
Notes 
a
 P-values calculated using a Kruskal Wallis test (P-values ≤ 0.05 indicated in bold type). 
b Cross sectional survey. 
c
 Number of samples tested by ELISA. Data on antibodies to the FC27 allele of MSP2 is provided in the Supplementary Material 
d P-values ≤ 0.05 when comparing antibody levels between children 1-3 years and children 7-10 years using a Mann Whitney U test (P-values not shown). 
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Table 5. Maintenance of antibodies to AMA1 and MSP2 between October 2003 and October 2004 
 
 
 
Seropositive (n)1 
 
October 2003 October 2004 Maintained seropositivity
2
 
    
AMA1(W2mef) 45.3%  (124) 36.5%  (100) 73.4%  (91) 
AMA1(HB3) 44.5%  (122) 36.1%  (99) 73.8%  (90) 
AMA1(3D7) 43.8%  (120) 34.7%  (95) 69.2%  (83) 
MSP2(3D7) 15.3%  (42) 9.1%  (25) 52.4%  (22) 
MSP2(FC27) 19.0% (52) 9.5%  (26) 42.3%  (22) 
Notes 
1 All children present at October 2003 and October 2004 cross sectional bleeds (n=274). 
2 Percentage of seropositive individuals in October 2003 who maintained their seropositive status in October 2004. 
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Figure 1 
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Figure 2 
 
 
Downloaded from https://academic.oup.com/jid/article-abstract/doi/10.1093/infdis/jix370/4060521/Declining-malaria-transmission-differentially
by Swansea University user
on 07 September 2017
